Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Colorcon
Johnson and Johnson
Baxter
Moodys

Last Updated: December 8, 2019

DrugPatentWatch Database Preview

Patent: 5,866,793

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,866,793
Title: Promoter for expressing foreign genes in monocotyledonous plants
Abstract:A DNA fragment for directing the expression of foreign or endogenous genes or RNA in cells of monocot plants. The fragment comprises a sequence corresponding to a first part of a putative type I starch branching enzyme gene (wbeI) present in wheat and a 5\'-region upstream of the gene, or a part of the sequence that is effective for increasing the expression of the foreign or endogenous gene in the plant cells. The indicated sequence contains two promoter regions, P1 and P2. A DNA fragment effective to increase expression comprises at least one of the promoter regions, or an effective part. The fragment can be obtained from a genomic library of wheat and can be fused to suitable genes and markers and inserted into suitable vectors for expression in transgenic monocot plants.
Inventor(s): Baga; Monica (Saskatoon, CA), Chibbar; Ravindra N. (Saskatoon, CA), Kartha; Kutty K. (Saskatoon, CA)
Assignee: National Research Council of Canada (Ottawa, CA)
Application Number:08/773,251
Patent Claims:see list of patent claims

Details for Patent 5,866,793

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial National Research Council of Canada (Ottawa, CA) 2016-06-03 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial National Research Council of Canada (Ottawa, CA) 2016-06-03 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial National Research Council of Canada (Ottawa, CA) 2016-06-03 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
McKinsey
Dow
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.